Remco Jan Geukes Foppen, Vincenzo Gioia, Alessio Zoccoli and Carlos N. Velez (2025). The Rise of Multimodal Language Models in Drug Development. A Featured Article European Pharmacological Review June 12. (LINK) Remco Jan Geukes Foppen, Vincenzo Gioia, Alessio Zoccoli and Carlos N. Velez (2025). From siloed data to breakthroughs: multimodal AI in drug discovery. A Featured Article in Drug Target Review June 11 (LINK) Marcella Zucca, Vincenzo Gioia, Remco Jan Geukes Foppen, Alessio Zoccoli (2025) Quando l'AI riflette il bias: le disuguaglianze di genere nei dataset. Agenda Digitale Maggio 2025. (LINK) Remco Jan Geukes Foppen, Vincenzo Gioia, Alessio Zoccoli and Carlos N. Velez (2025) Beyond the Lab: Clinical Trial Report. Using clinical genomics and AI in drug development to elevate success Drug Target Review (LINK) Remco Jan Geukes Foppen, Vincenzo Gioia, Alessio Zoccoli (2025). Scoperta di nuovi farmaci: che succede se l’AI sostituisce il caso? Agenda Digitale (LINK) Remco Jan Geukes Foppen, Vincenzo Gioia, Alessio Zoccoli and Carlos N. Velez (2025). Early evidence and emerging trends: How AI is shaping drug discovery and clinical development. PART 3. A Featured Article in Drug Target Review April Edition (LINK) Remco Jan Geukes Foppen, Vincenzo Gioia, Alessio Zoccoli and Carlos N. Velez (2025) Pharma Horizons: Artificial Intelligence report. The Rise of Multimodal Language Models in Drug Development. European Pharmacological Review (LINK) Remco Jan Geukes Foppen, Vincenzo Gioia, Alessio Zoccoli and Carlos N. Velez (2025) Beyond the Lab – Artificial Intelligence report. Navigating the AI revolution: a roadmap for pharma’s future. Drug Target Review (LINK) Remco Jan Geukes Foppen, Vincenzo Gioia, Alessio Zoccoli and Carlos N. Velez (2025) Navigating the AI revolution: a roadmap for pharma’s future. PART 2. A Featured Article in Drug Target Review March Edition (LINK) Remco Jan Geukes Foppen, Vincenzo Gioia, Alessio Zoccoli and Carlos N. Velez (2025) Using clinical genomics and AI in drug development to elevate success. Drug Target Review February Edition (LINK) Remco Jan Geukes Foppen, Vincenzo Gioia, Alessio Zoccoli (2025). Nuovi farmaci grazie all’AI: ecco le svolte attese nel 2025. Agenda Digitale (LINK) Remco Jan Geukes Foppen, Vincenzo Gioia, Shreya Gupta, Curtis Johnson, John Giantsidis, Maria Papademetris (2024). Methodology for Safe and Secure AI in Diabetes Management in Journal of Diabetes Science and Technology (LINK) Remco Jan Geukes Foppen, Vincenzo Gioia, Alessio Zoccoli (November edition 2024). Scienze della vita: la svolta degli Small Language Model, Agenda Digitale (LINK) Remco Jan Geukes Foppen, Vincenzo Gioia and Carlos N. Velez (October edition 2024). AI, PoS, and ROI: An alphabet soup of 21st Century drug development PART 2, Life Science Leader (LINK) Remco Jan Geukes Foppen, Vincenzo Gioia and Carlos N. Velez (October edition 2024). AI, PoS, and ROI: An alphabet soup of 21st Century drug development PART 1, Life Science Leader (LINK) Vincenzo Gioia, Remco Jan Geukes Foppen (September edition 2024). ‘Explainambiguity:’ When What You Think Is Not What You Get, Life Science Leader (LINK) Vincenzo Gioia, Remco Jan Geukes Foppen (July edition 2024). Correct But Misleading: AI Hallucinations In Complex Decision-Making, Life Science Leader (LINK) Cross-published on multiple outlets of Life Science Connect: Clinical Leader, Pharmaceutical Online, Outsourced Pharma, Bioprocess Online, Cell & Gene, Clinical Tech Leader and Drug Discovery Online. Featured in ISPE Newsletter (International Society for Pharmaceutical Engineering) Vincenzo Gioia, Remco Jan Geukes Foppen (June edition 2024). Beware AI Hallucinations, Life Science Leader (LINK) Cross-published on multiple outlets of Life Science Connect: Clinical Leader, Pharmaceutical Online, Outsourced Pharma, Bioprocess Online, Cell & Gene, and Drug Discovery Online. John Giantsidis, Remco Jan Geukes Foppen (April edition 2024). New FDA Draft Guidance: Data Monitoring Committees In Clinical Trials. Clinical Leader (LINK) Remco Jan Geukes Foppen, Vincenzo Gioia (February 2024). AI Hallucinations in Clinical Trial Predictions, Asset Valuations and Portfolio Management. Medium (LINK) J. Giantsidis, R.J. Geukes Foppen (2023). Framework to maximize drug development with use of Artificial Intelligence in a regulatory FDA response (LINK) A. Alfano, R. Foppen, C. Savklì, K. Bigos, V. Singh (2021). A best-in-class AI / ML platform, leveraged for Predictive Analytics in Drug Development Strategy (LINK) R.J. Geukes Foppen (2004). In skeletal muscle the relaxation of the resting membrane potential induced by K+ permeability changes is dependent on Cl- transport. Pflügers Archiv–European Journal of Physiology, 447(4), 416–425 (LINK) R.J. Geukes Foppen & J. Siegenbeek van Heukelom (2003) Isoprenaline stimulated differential adrenergic response of K+ channels in skeletal muscle in hypokalemic conditions. Pflügers Archiv–European Journa